Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Influence of a 3' Terminal Ribozyme on AgoshRNA Biogenesis and Activity.

Herrera-Carrillo E, Gao Z, Berkhout B.

Mol Ther Nucleic Acids. 2019 Jun 7;16:452-462. doi: 10.1016/j.omtn.2019.04.001. Epub 2019 Apr 8.

2.

Boosting AgoshRNA activity by optimized 5'-terminal nucleotide selection.

Gao Z, Berkhout B, Herrera-Carrillo E.

RNA Biol. 2019 Jul;16(7):890-898. doi: 10.1080/15476286.2019.1599259. Epub 2019 Apr 16.

3.

The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.

Darcis G, Binda CS, Klaver B, Herrera-Carrillo E, Berkhout B, Das AT.

Viruses. 2019 Mar 13;11(3). pii: E255. doi: 10.3390/v11030255.

4.

A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System.

Gao Z, Herrera-Carrillo E, Berkhout B.

Mol Ther Nucleic Acids. 2019 Mar 1;14:32-40. doi: 10.1016/j.omtn.2018.10.016. Epub 2018 Nov 1.

5.

Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA.

Gao Z, Herrera-Carrillo E, Berkhout B.

RNA Biol. 2018;15(12):1458-1467. doi: 10.1080/15476286.2018.1551703. Epub 2018 Nov 29.

6.

RNA Polymerase II Activity of Type 3 Pol III Promoters.

Gao Z, Herrera-Carrillo E, Berkhout B.

Mol Ther Nucleic Acids. 2018 Sep 7;12:135-145. doi: 10.1016/j.omtn.2018.05.001. Epub 2018 May 8.

7.

Delineation of the Exact Transcription Termination Signal for Type 3 Polymerase III.

Gao Z, Herrera-Carrillo E, Berkhout B.

Mol Ther Nucleic Acids. 2018 Mar 2;10:36-44. doi: 10.1016/j.omtn.2017.11.006. Epub 2017 Nov 21.

8.

Dicer-independent processing of small RNA duplexes: mechanistic insights and applications.

Herrera-Carrillo E, Berkhout B.

Nucleic Acids Res. 2017 Oct 13;45(18):10369-10379. doi: 10.1093/nar/gkx779. Review.

9.

Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.

Herrera-Carrillo E, Liu YP, Berkhout B.

Hum Gene Ther Methods. 2017 Aug;28(4):177-190. doi: 10.1089/hgtb.2017.036. Review.

10.

Mutation of nucleotides around the +1 position of type 3 polymerase III promoters: The effect on transcriptional activity and start site usage.

Gao Z, Harwig A, Berkhout B, Herrera-Carrillo E.

Transcription. 2017;8(5):275-287. doi: 10.1080/21541264.2017.1322170. Epub 2017 Jun 9.

11.

Influence of the loop size and nucleotide composition on AgoshRNA biogenesis and activity.

Herrera-Carrillo E, Harwig A, Berkhout B.

RNA Biol. 2017 Nov 2;14(11):1559-1569. doi: 10.1080/15476286.2017.1328349. Epub 2017 Nov 3.

12.

Silencing of HIV-1 by AgoshRNA molecules.

Herrera-Carrillo E, Harwig A, Berkhout B.

Gene Ther. 2017 Aug;24(8):453-461. doi: 10.1038/gt.2017.44. Epub 2017 May 29.

PMID:
28553929
13.

Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection.

Herrera-Carrillo E, Berkhout B.

PLoS One. 2017 May 24;12(5):e0177935. doi: 10.1371/journal.pone.0177935. eCollection 2017.

14.

Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.

Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, Herrera Carrillo E, Brandsma JH, Poot RA, Berkhout B, Neyts J, Peppelenbosch MP, Pan Q.

Antiviral Res. 2017 Apr;140:1-12. doi: 10.1016/j.antiviral.2017.01.005. Epub 2017 Jan 8.

15.

The influence of the 5΄-terminal nucleotide on AgoshRNA activity and biogenesis: importance of the polymerase III transcription initiation site.

Herrera-Carrillo E, Gao ZL, Harwig A, Heemskerk MT, Berkhout B.

Nucleic Acids Res. 2017 Apr 20;45(7):4036-4050. doi: 10.1093/nar/gkw1203.

16.

Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas.

Herrera-Carrillo E, Berkhout B.

Biochem Soc Trans. 2016 Oct 15;44(5):1355-1365. Review.

PMID:
27911718
17.

Bone Marrow Gene Therapy for HIV/AIDS.

Herrera-Carrillo E, Berkhout B.

Viruses. 2015 Jul 17;7(7):3910-36. doi: 10.3390/v7072804. Review.

18.

Deep Sequence Analysis of AgoshRNA Processing Reveals 3' A Addition and Trimming.

Harwig A, Herrera-Carrillo E, Jongejan A, van Kampen AH, Berkhout B.

Mol Ther Nucleic Acids. 2015 Jul 14;4:e247. doi: 10.1038/mtna.2015.19.

19.

Towards Antiviral shRNAs Based on the AgoshRNA Design.

Liu YP, Karg M, Herrera-Carrillo E, Berkhout B.

PLoS One. 2015 Jun 18;10(6):e0128618. doi: 10.1371/journal.pone.0128618. eCollection 2015.

20.

Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs.

Liu YP, Karg M, Harwig A, Herrera-Carrillo E, Jongejan A, van Kampen A, Berkhout B.

RNA Biol. 2015;12(1):92-100. doi: 10.1080/15476286.2015.1017204.

21.

Gene therapy strategies to block HIV-1 replication by RNA interference.

Herrera-Carrillo E, Berkhout B.

Adv Exp Med Biol. 2015;848:71-95. doi: 10.1007/978-1-4939-2432-5_4. Review.

PMID:
25757616
22.

Toward optimization of AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the top and bottom base pairs.

Herrera-Carrillo E, Harwig A, Berkhout B.

RNA Biol. 2015;12(4):447-56. doi: 10.1080/15476286.2015.1022024.

23.

The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.

Herrera-Carrillo E, Berkhout B.

Gene Ther. 2015 Jun;22(6):485-95. doi: 10.1038/gt.2015.11. Epub 2015 Feb 26.

PMID:
25716532
24.

Potential mechanisms for cell-based gene therapy to treat HIV/AIDS.

Herrera-Carrillo E, Berkhout B.

Expert Opin Ther Targets. 2015 Feb;19(2):245-63. doi: 10.1517/14728222.2014.980236. Epub 2014 Nov 12. Review.

PMID:
25388088
25.

Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity.

Herrera-Carrillo E, Harwig A, Liu YP, Berkhout B.

RNA. 2014 Sep;20(9):1410-8. doi: 10.1261/rna.043950.113. Epub 2014 Jul 17.

26.

The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin.

Herrera-Carrillo E, Paxton WA, Berkhout B.

J Virol Methods. 2014 Jul;203:88-96. doi: 10.1016/j.jviromet.2014.03.021. Epub 2014 Mar 31.

PMID:
24698763
27.

The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Herrera-Carrillo E, Liu YP, Berkhout B.

Mol Ther. 2014 Mar;22(3):596-606. doi: 10.1038/mt.2013.280. Epub 2013 Dec 12.

Supplemental Content

Loading ...
Support Center